Travere Therapeutics, Inc. (TVTX)
50.65
-0.91
(-1.76%)
USD |
NASDAQ |
Nov 13, 16:00
50.70
+0.05
(+0.10%)
After-Hours: 07:26
Travere Therapeutics Debt to Equity Ratio : 27.28 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 27.28 |
| June 30, 2026 | 25.16 |
| March 31, 2026 | 3.319 |
| December 31, 2025 | 2.863 |
| September 30, 2025 | 4.482 |
| June 30, 2025 | 12.20 |
| March 31, 2025 | 12.20 |
| December 31, 2024 | 6.798 |
| September 30, 2024 | -13.21 |
| June 30, 2024 | 26.62 |
| March 31, 2024 | 5.454 |
| December 31, 2023 | 2.016 |
| September 30, 2023 | 1.449 |
| June 30, 2023 | 3.487 |
| March 31, 2023 | 2.151 |
| December 31, 2022 | 9.509 |
| September 30, 2022 | 4.049 |
| June 30, 2022 | 2.605 |
| March 31, 2022 | 1.964 |
| December 31, 2021 | 0.8672 |
| September 30, 2021 | 0.8459 |
| June 30, 2021 | 0.7716 |
| March 31, 2021 | 0.6903 |
| December 31, 2020 | 1.155 |
| September 30, 2020 | 0.8008 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.685 |
| March 31, 2020 | 0.9297 |
| December 31, 2019 | 0.9714 |
| September 30, 2019 | 0.8653 |
| June 30, 2019 | 0.7608 |
| March 31, 2019 | 0.8118 |
| December 31, 2018 | 0.6836 |
| September 30, 2018 | 0.6743 |
| June 30, 2018 | 0.1576 |
| March 31, 2018 | 0.1511 |
| December 31, 2017 | 0.1538 |
| September 30, 2017 | 0.1475 |
| June 30, 2017 | 0.1513 |
| March 31, 2017 | 0.1481 |
| December 31, 2016 | 0.1443 |
| September 30, 2016 | 0.1439 |
| June 30, 2016 | 0.1403 |
| March 31, 2016 | 0.1376 |
| December 31, 2015 | 0.1464 |
| September 30, 2015 | 0.1503 |
| June 30, 2015 | 0.5619 |
| March 31, 2015 | 0.4998 |
| December 31, 2014 | -2.249 |
| September 30, 2014 | -8.176 |
| June 30, 2014 | 77.63 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 0.3099 |
| TG Therapeutics, Inc. | 1.318 |
| Viridian Therapeutics, Inc. | 0.4189 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
| BioMarin Pharmaceutical, Inc. | 0.6723 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 848.23M |
| Total Liabilities (Quarterly) | 825.64M |
| Shareholders Equity (Quarterly) | 22.58M |
| Current Ratio | 3.003 |
| Net Debt Paydown Yield | -0.77% |